Abstract
In patients with elevated progesterone levels at the beginning of an ART (assisted reproductive technology) treatment cycle, the outcome of controlled ovarian stimulation (COS) may be inappropriate. A prospective cohort study was conducted to investigate whether the administration of a GnRH antagonist prior to the start of COS in these patients could lead to a similar pregnancy rate than in case of normal progesterone. Four hundred eighty-four patients were included in this study between February 2009 and July 2009. COS was initiated on day 2 of the cycle when estradiol (E2) and progesterone (P) serum levels were normal (E2 ≤ 80 pg/ml, P ≤ 1.5 ng/ml; “normal P group”). When serum progesterone was > 1.5 ng/ml on day 2 of the cycle (“high P group”), stimulation was not initiated, instead a GnRH antagonist was administered at a dosage of 0.25 mg during three consecutive days. In both study groups, efficient ovarian stimulation ensued and pregnancy rates did not diverge significantly. The results of the study led us to conclude that administration of a GnRH antagonist normalizes progesterone levels in those cases with isolated elevated serum progesterone levels at the start of the ART treatment cycle, and that this pretreatment is compatible with adequate ovarian stimulation and results in acceptable pregnancy rates.
Keywords: GnRH antagonist, IVF, ICSI, elevated progesterone, ovarian stimulation
Current Pharmaceutical Biotechnology
Title: Administration of GnRH Antagonists in Case of Elevated Progesterone at Initiation of the Cycle: A Prospective Cohort Study
Volume: 12 Issue: 3
Author(s): Christophe Blockeel, Miriam Baumgarten, Michel De Vos, Greta Verheyen and Paul Devroey
Affiliation:
Keywords: GnRH antagonist, IVF, ICSI, elevated progesterone, ovarian stimulation
Abstract: In patients with elevated progesterone levels at the beginning of an ART (assisted reproductive technology) treatment cycle, the outcome of controlled ovarian stimulation (COS) may be inappropriate. A prospective cohort study was conducted to investigate whether the administration of a GnRH antagonist prior to the start of COS in these patients could lead to a similar pregnancy rate than in case of normal progesterone. Four hundred eighty-four patients were included in this study between February 2009 and July 2009. COS was initiated on day 2 of the cycle when estradiol (E2) and progesterone (P) serum levels were normal (E2 ≤ 80 pg/ml, P ≤ 1.5 ng/ml; “normal P group”). When serum progesterone was > 1.5 ng/ml on day 2 of the cycle (“high P group”), stimulation was not initiated, instead a GnRH antagonist was administered at a dosage of 0.25 mg during three consecutive days. In both study groups, efficient ovarian stimulation ensued and pregnancy rates did not diverge significantly. The results of the study led us to conclude that administration of a GnRH antagonist normalizes progesterone levels in those cases with isolated elevated serum progesterone levels at the start of the ART treatment cycle, and that this pretreatment is compatible with adequate ovarian stimulation and results in acceptable pregnancy rates.
Export Options
About this article
Cite this article as:
Blockeel Christophe, Baumgarten Miriam, De Vos Michel, Verheyen Greta and Devroey Paul, Administration of GnRH Antagonists in Case of Elevated Progesterone at Initiation of the Cycle: A Prospective Cohort Study, Current Pharmaceutical Biotechnology 2011; 12 (3) . https://dx.doi.org/10.2174/138920111794480633
DOI https://dx.doi.org/10.2174/138920111794480633 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Targeting CCK Receptors in Human Cancers
Current Topics in Medicinal Chemistry Fertility Preservation for Young Women with Cancer: Hope for the Future
Current Women`s Health Reviews A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews Novel Research Strategies of Benzimidazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued) Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Omega-3 Fatty Acids: Role in the Prevention and Treatment of Psychiatric Disorders
Current Psychiatry Reviews Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry The Anti-Inflammatory Role of Annexin-1 in Arthritis
Current Rheumatology Reviews Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview
Mini-Reviews in Medicinal Chemistry Fluorescent Agonists and Antagonists for Vasopressin/Oxytocin G Protein-Coupled Receptors: Usefulness in Ligand Screening Assays and Receptor Studies
Mini-Reviews in Medicinal Chemistry Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hormone Replacement Therapy in Rheumatoid Arthritis
Current Rheumatology Reviews Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Pharmacology of Appetite Suppression: Implication for the Treatment of Obesity
Current Drug Targets Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis
Current Gene Therapy Current and Future Applications of Probiotics
Current Nutrition & Food Science Male Contraception: An Overview of the Potential Target Events
Endocrine, Metabolic & Immune Disorders - Drug Targets